相似文献
1
Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose.
JAMA Intern Med. 2021 Nov 1;181(11):1530-1533. doi: 10.1001/jamainternmed.2021.3779.
2
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
JAMA Cardiol. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833.
3
Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
Clin Microbiol Infect. 2022 Jun;28(6):885.e1-885.e5. doi: 10.1016/j.cmi.2022.02.010. Epub 2022 Feb 16.
4
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
BMC Cancer. 2021 Dec 27;21(1):1354. doi: 10.1186/s12885-021-09097-5.
5
Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
Am J Cardiol. 2022 Mar 15;167:155-157. doi: 10.1016/j.amjcard.2021.12.007. Epub 2022 Jan 19.
6
Mixing vaccines may boost immune responses.
Science. 2021 Jun 11;372(6547):1138. doi: 10.1126/science.372.6547.1138.
7
Is a single dose of mRNA vaccine sufficient for COVID-19 survivors?
J Med Virol. 2021 Jul;93(7):4083-4084. doi: 10.1002/jmv.26915. Epub 2021 Mar 14.
8
Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
JAMA. 2021 Oct 12;326(14):1390-1399. doi: 10.1001/jama.2021.15072.
9
Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience.
Allergy Asthma Proc. 2021 Sep 1;42(5):395-399. doi: 10.2500/aap.2021.42.210069.
10
Immediate reactions after mRNA SARS-CoV-2 vaccination.
CMAJ. 2021 Dec 6;193(48):E1842. doi: 10.1503/cmaj.211581. Epub 2021 Nov 12.
引用本文的文献
1
Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study.
Trop Dis Travel Med Vaccines. 2025 Aug 14;11(1):30. doi: 10.1186/s40794-025-00266-z.
2
COVID-19 vaccination: challenges in the pediatric population.
Front Public Health. 2025 Jan 29;12:1390951. doi: 10.3389/fpubh.2024.1390951. eCollection 2024.
3
Risk Factors Associated with Cutaneous Reactions Following COVID-19 Vaccine Immunisation: A Registry-Based Case-Control Study.
Malays J Med Sci. 2024 Jun;31(3):133-148. doi: 10.21315/mjms2024.31.3.10. Epub 2024 Jun 27.
4
A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination.
J Allergy Clin Immunol. 2024 Jun;153(6):1634-1646. doi: 10.1016/j.jaci.2024.03.001. Epub 2024 Mar 7.
5
Allergic reactions to the Ad26.COV2.S vaccine in South Africa.
J Allergy Clin Immunol Glob. 2021 Dec 9;1(1):2-8. doi: 10.1016/j.jacig.2021.12.002. eCollection 2022 Feb.
6
Suspected Anaphylactic Reaction Following Second Dose of the Pfizer-BioNTech (BNT162b2) Coronavirus Vaccine in a Geriatric Female.
HCA Healthc J Med. 2022 Dec 30;3(6):349-354. doi: 10.36518/2689-0216.1452. eCollection 2022.
7
The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital.
Vaccines (Basel). 2023 Apr 27;11(5):903. doi: 10.3390/vaccines11050903.
8
Safety of COVID-19 vaccination in children with prior allergic reactions or mast cell disorders.
Clin Transl Allergy. 2023 May;13(5):e12267. doi: 10.1002/clt2.12267.
9
Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization.
Front Allergy. 2023 May 3;4:1056619. doi: 10.3389/falgy.2023.1056619. eCollection 2023.
10
Anaphylactic reactions after COVID-19 vaccination in Germany.
Allergol Select. 2023 Mar 31;7:90-100. doi: 10.5414/ALX02374E. eCollection 2023.
Zotero 插件